Table 2.

Types of AdMs

AdMs (n = 35)SyM (n = 16)SPM in TI patients with NDMM (n = 19)SPM in patients treated with Len (n = 12)
Hematologic malignancies, n (%) 9 (26) 8 (50) 1 (5) 1 (8) 
Myelodysplastic syndromes   
Myeloproliferative neoplasms   
Lymphoid blood diseases   
Acute lymphoblastic leukemia 
Solid malignancies, n (%) 26 (74) 8 (50) 18 (95) 11 (92) 
Colorectal 
Prostate 
Breast 
Lung  
Bladder  
Kidney  
Melanoma  
Head and neck  
Liver and bile duct  
Pseudomyxoma peritonei  
AdMs (n = 35)SyM (n = 16)SPM in TI patients with NDMM (n = 19)SPM in patients treated with Len (n = 12)
Hematologic malignancies, n (%) 9 (26) 8 (50) 1 (5) 1 (8) 
Myelodysplastic syndromes   
Myeloproliferative neoplasms   
Lymphoid blood diseases   
Acute lymphoblastic leukemia 
Solid malignancies, n (%) 26 (74) 8 (50) 18 (95) 11 (92) 
Colorectal 
Prostate 
Breast 
Lung  
Bladder  
Kidney  
Melanoma  
Head and neck  
Liver and bile duct  
Pseudomyxoma peritonei  

or Create an Account

Close Modal
Close Modal